Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 10/20 | 0.65 |
| ▸ | F13A1 | P00488 | 8/20 | 0.65 |
| ▸ | TGM1 | P22735 | 5/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16013381 | 0.91 | GAA (0.65) | TGM2F13A1TGM1GAATGM3 | |
| SCHEMBL5437122 | 0.88 | TGM2 (0.52) | TGM2F13A1TGM1TGM3LMNA | |
| SCHEMBL2226727 | 0.86 | TGM2 (0.64) | TGM2F13A1TGM1TGM3LMNA | |
| SCHEMBL14490312 | 0.85 | TGM2 (0.52) | TGM2F13A1TGM1TGM3BACE1 | |
| SCHEMBL5442111 | 0.85 | TGM2 (0.64) | TGM2F13A1TGM1TGM3ALDH1A1 | |
| SCHEMBL19869971 | 0.85 | GAA (0.65) | TGM2F13A1TGM1GAATGM3 | |
| SCHEMBL25176606 | 0.84 | TGM2 (0.51) | TGM2F13A1TGM1TGM3LMNA | |
| SCHEMBL2818818 | 0.83 | TGM2 (0.50) | TGM2F13A1TGM1GAATGM3 | |
| SCHEMBL5442261 | 0.83 | TGM2 (0.52) | TGM2F13A1TGM1TGM3ALDH1A1 | |
| SCHEMBL18498657 | 0.83 | TGM2 (0.50) | TGM2F13A1TGM1TGM3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3265453-B1 | NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 | BOEHRINGER INGELHEIM INT (DE) | 2022-06-29 | — | — | EP | disclosed |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-03 | — | — | US | disclosed |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BRD9, BRD1, BRD2 | TGM2 4527/4885F13A1 4141/4885TGM1 3858/4885 |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BRD9, BRD1, BRD2 | TGM2 4478/4885F13A1 4033/4885TGM1 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.